Rep. Maria Elvira Salazar Buys Biogen Inc. (NASDAQ:BIIB) Stock

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $50,001 and $100,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
• Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $194.24 on Thursday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The stock’s 50-day moving average is $188.07 and its 200 day moving average is $184.03. The stock has a market cap of $28.68 billion, a price-to-earnings ratio of 20.84 and a beta of 0.20. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently added to or reduced their stakes in BIIB. Reflection Asset Management bought a new stake in Biogen in the fourth quarter worth $25,000. WPG Advisers LLC increased its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the last quarter. Accredited Wealth Management LLC increased its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares during the last quarter. First Horizon Corp purchased a new stake in Biogen during the fourth quarter valued at $30,000. Finally, WFA of San Diego LLC purchased a new stake in Biogen during the second quarter valued at $32,000. 87.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada lifted their price objective on Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 27th. Canaccord Genuity Group lifted their price target on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Needham & Company LLC upgraded Biogen from a “hold” rating to a “buy” rating and set a $255.00 price target on the stock in a research report on Monday. Citigroup lifted their price target on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lifted their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.